REMICADE
January 1st, 2002
BY KEITH NUTHALLDOCTORS treating Chron's disease and rheumatoid arthritis with the drug Remicade must ensure that their patients have tuberculosis, (including latent TB), or other severe infections including sepsis, abscesses or "opportunistic infections," the European Agency for the Evaluation of Medicinal Products, (EMEA), has said. It has warned that until mid-2001, 202 Remicade patients died after developing serious infections; also 130 cases of active TB have been reported, some fatal. Said EMEA: "Before starting treatment with Remicade, all patients must be ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.